Skip to main content
OpenTrials
Completed

NCT Number: NCT05316350

Withings ECG-app Study

The aim of the study is to evaluate the performance of Withings HWA10 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Henri-Mondor Hospital, Créteil, Île-de-France Region, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female who are 22 years of age or older
  • Subject able to read, understand, and provide written informed consent
  • Subject willing and able to participate in the study procedures as described in the consent form
  • Subject able to communicate effectively with and willing to follow instructions from the study staff
  • Have a wrist circumference between 140 mm and 210 mm (measured at "band center" on the preferred wrist, 1cm from the bone. This location is determined by asking the volunteer to put on a normal wrist-watch and marking the skin with a pen/marker to outline the edges of the band.)

Exclusion criteria

  • Vulnerable subject with regard to regulations in force
  • Subject who is deprived of liberty by judicial, medical or administrative decision,
  • Underage subject,
  • Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form,
  • Subject within several of the above categories,
  • Subject who refused to participate in the study,
  • Subject mentally impaired resulting in limited ability to cooperate
  • Subject in physical incapacity to wear a watch on one wrist and place the other hand on top of the watch
  • Subject with electrical stimulation by pacemaker
  • Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)
  • Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)
  • Acute pulmonary embolism or pulmonary infarction, within 90 days of screening
  • Stroke or transient ischemic attack within 90 days of screening
  • Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).
  • History of abnormal life-threatening rhythms (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)
  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites
  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices

Treatment and study plan

Electrocardiogram recording

Device

ECG recording with investigational device

Primary outcomes

  1. Co-primary outcomes

    Time frame: 4 months

    Sensitivity (percentage of true positives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.

  2. Co-primary outcomes

    Time frame: 4 months

    Specificity (percentage of true negatives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.

Secondary outcomes

  1. Evaluation of the classification into heart rate subgroups

    Time frame: 4 months

    The classification into heart rate subgroups will be evaluated for the pairs of strips such that the rhythm classification of the 12-lead ECG is either SR or AF and such that the strip generated by the SUT is classified as either SR or AF. The evaluation will be assessed with the concordance of classifications, i.e. the percentage P of identical classifications by the SUT and the reference method, into each of the four following subgroups:

    • SR with a HR between 50 and 99 bpm
    • SR with a HR between 100 and 150 bpm
    • AF with a HR between 50 and 99 bpm
    • AF with a HR between 100 and 150 bpm
  2. Clinical Equivalence of ECG waveforms

    Time frame: 4 months

    Clinical Equivalence of ECG waveforms will be qualitatively and quantitatively assessed between the 6-leads generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG by a board of certified cardiologists:

    The visibility and polarity of the P waves, QRS complexes and T waves will be determined by cardiologists and according to a set of predetermined rules. For each type of wave (P, QRS and T),

  3. Clinical Equivalence of ECG waveforms

    Time frame: 4 months

    The durations of the QT intervals, QRS complex widths, and PR intervals will be measured by cardiologists with a caliper and according to a set of predetermined rules for each of the 6 leads of the strips generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG.

  4. Heart Rate equivalence

    Time frame: 4 months

    heart rate will be determined by independent cardiologists, or cardiac technicians supervised by cardiologists, from each six-channel strip recorded with the SUT and from each lead I, II, III, aVR, aVL, aVF of the 12-lead reference ECG

Sponsors and collaborators

Lead sponsor

Withings

Industry

Collaborators

  • Syntactx

Registry information

Official study title

Validation of HWA10 With Withings ECG-app for the Detection of Atrial Fibrillation

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 7, 2022
Registry last updated
Mar 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.